This product is a vasculostatin expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP6 and two copies of ICP34.5 deleted. ICP6 encodes a viral ribonucleotide reductase (vRR) function that allows replication of wild-type HSV to occur even in quiescent cells, such as the neurons. ICP34.5 protein, is important for viral replication, viral exit from infected cells, prevention of the premature shut-off of protein synthesis in the infected host, and neurovirulence. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔICP6, ΔΔICP34.5)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification
ΔICP6, ΔΔICP34.5
Promoter
CMV
Transgene
vasculostatin
Type of Transgene
Cytokine
Related Target/Protein
Vasculostatin
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Glioma
Transgene
Alternative Names
vasculostatin
Information
Introduction
Vasculostatin, a proteolytic fragment of brain Angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor, inhibited migration of endothelial cells in vitro and dramatically reduced in vivo angiogenesis.
Customer Reviews and Q&As
There are currently no customer reviews or questions for vasculostatin-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-vasculostatin (CyOV-0036XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.
Datasheet